Cns Pharmaceuticals Inc

NASDAQ:CNSP   3:59:42 PM EDT
2.29
+0.10 (+4.57%)
Products

CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted For FDA Review

Published: 11/09/2020 13:47 GMT
CNS Pharmaceuticals, Inc. (CNSP) - Cns Pharmaceuticals Announces Adaptive Trial Design for Berubicin Phase 2 Clinical Trial to Be Submitted for FDA Review.